A Retrospective, Single Centre, Non-interventional Study Investigating the Effect of Ryzodeg (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in Lebanon
Latest Information Update: 15 Nov 2022
Price :
$35 *
At a glance
- Drugs Insulin degludec/insulin aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 11 Nov 2022 Status changed from recruiting to completed.
- 30 Sep 2021 Planned End Date changed from 30 Sep 2021 to 30 Nov 2021.
- 30 Sep 2021 Status changed from not yet recruiting to recruiting.